glp 1 agonist trials Lilly orforglipron oral GLP-1 phase 3 weight loss trial Emerging Trends in the Development
Description
We review market size and projections for the GLP-1 sector (powered by the obesity/metabolic disease epidemic), and we highlight Lillys blockbuster sales, R&D moves, partnerships, and how it stacks up against competitors like Novo Nordisk
They are also administered at different doses and last for different durations
10.7326/m17-2786
doi: 10.1002/(ISSN)1096-9136 [DOI] [PubMed] [Google Scholar] 28
